Okomera

Paris, France Founded: 2020 • Age: 6 yrs
Microfluidic chip device for in vitro cancer testing is developed.
Request Access

About Okomera

Okomera is a company based in Paris (France) founded in 2020 by Aimee Wessel, Sandra Jernstrom, Raphael Tomasi, and Charles Baroud.. Okomera has raised $11.17 million across 1 funding round from investors including Polytechnique Ventures, Berkeley SkyDeck Fund and Resonance. Okomera offers products and services including 3D Organoid Screening Platform and AI Analysis Platform. Okomera operates in a competitive market with competitors including Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.

  • Headquarter Paris, France
  • Founders Aimee Wessel, Sandra Jernstrom, Raphael Tomasi, Charles Baroud
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $11.17 M (USD)

    in 1 rounds

  • Latest Funding Round
    $11.17 M (USD), Seed

    Dec 20, 2023

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Okomera

Okomera offers a comprehensive portfolio of products and services, including 3D Organoid Screening Platform and AI Analysis Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Automates high-throughput screening of organoids for cancer research

Provides end-to-end AI for organoid data processing in drug testing

Funding Insights of Okomera

Okomera has successfully raised a total of $11.17M through 1 strategic funding round. The most recent funding activity was a Seed round of $11.17 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Seed — $11.2M
  • First Round

    (20 Dec 2023)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2023 Amount Seed - Okomera Valuation Polytechnique Ventures , Berkeley SkyDeck Fund
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Okomera

Okomera has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Polytechnique Ventures, Berkeley SkyDeck Fund and Resonance. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
A seed fund is managed to support startups from Ecole Polytechnique ecosystem.
Founded Year Domain Location
Investments are directed toward early-stage tech startups by Resonance.
Founded Year Domain Location
Venture capital fund focused on multiple sectors
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Okomera

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Okomera

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Okomera Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Okomera

Okomera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Digital sequencing technology for cancer detection is developed.
domain founded_year HQ Location
Developer of cell-free DNA testing for oncology, women’s health, and organ health
domain founded_year HQ Location
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
domain founded_year HQ Location
Genomics-based diagnostic tests for cancer are provided.
domain founded_year HQ Location
Molecular cancer diagnostic products are developed using patented AMP technology.
domain founded_year HQ Location
Health risks are identified through online genetic and diagnostic testing.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Okomera

Frequently Asked Questions about Okomera

When was Okomera founded?

Okomera was founded in 2020 and raised its 1st funding round 3 years after it was founded.

Where is Okomera located?

Okomera is headquartered in Paris, France.

Who is the current CEO of Okomera?

Aimee Wessel is the current CEO of Okomera. They have also founded this company.

Is Okomera a funded company?

Okomera is a funded company, having raised a total of $11.17M across 1 funding round to date. The company's 1st funding round was a Seed of $11.17M, raised on Dec 20, 2023.

What does Okomera do?

Okomera was founded in 2020 in Paris, France, within the biotechnology sector. A device employing microfluidic chips for in vitro cancer testing is developed. Proprietary technology is utilized for personalized treatments and evaluation of cancer cells in 3D spheroids. Tumor biopsies are analyzed through this method, supporting research in oncology applications.

Who are the top competitors of Okomera?

Okomera's top competitors include Guardant Health, Juno Therapeutics and Foundation Medicine.

What products or services does Okomera offer?

Okomera offers 3D Organoid Screening Platform and AI Analysis Platform.

Who are Okomera's investors?

Okomera has 4 investors. Key investors include Polytechnique Ventures, Berkeley SkyDeck Fund, Resonance, and Otium Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available